

JS 2 cancelled
36. A method according to claim 34, wherein Raloxifen is administered after administration of said LHRH analogue.

42. A method according to claim 41, wherein said LHRH analogue is Antide.

JS 3
43. A method according to claim 41, wherein said LHRH analogue is Ac-D-Nal-D-Cpa-D-Pal-Ser-Tyr-D-Cit-Leu-Lys(Mor)-Pro-D-Ala-NH₂.

44. A method of inhibiting LHRH analog-induced detrimental side effects due to the administration of an LHRH analog to a patient, wherein said detrimental side effect is reduction in bone density, comprising administering to a patient in need thereof an effective amount of Raloxifen.--

Please add the following new claims :

JS 1
JS 4
~~--51. A method for ameliorating LHRH analogue-induced reduction in bone density in a patient comprising administering to said patient one or more LHRH analogues and Raloxifen or a derivative thereof wherein said one or more LHRH analogues and Raloxifen, or a derivative thereof, are administered sequentially or simultaneously.~~

52. A method of inhibiting LHRH analog-induced detrimental side effects due to the administration of an LHRH analog to a patient, wherein said detrimental side effect is reduction in bone density, comprising administering to a patient in need thereof an effective amount of Raloxifen or a derivative thereof.--
